Donate
Public Comment Period Open

Make 340B Work for Patients

The Health Resources and Services Administration (HRSA) is seeking public input on a potential 340B rebate model. Patients deserve transparency and a clear benefit from these savings.

Docket No. HRSA-2026-03042 | Deadline: April 20, 2026
Takes less than 5 minutes.
Download the Toolkit
Submit Your Comment
Tablet with Regulations.gov open
Woman typing at a computer
Why This Matters

Patients Should Benefit from 340B Savings

The 340B Drug Pricing Program allows certain hospitals and providers to purchase outpatient medications at significant government-mandated discounts. It was designed to stretch resources and support patient care.

Yet many patients still face high out-of-pocket costs and are rarely told when 340B pricing applies to their prescriptions. Transparency into how those savings are used remains limited.

HRSA is now evaluating whether a rebate model could improve how discounts are tracked and administered.

This is a critical moment to ensure the program works as intended — and that patients see measurable benefit.

This is not a finalized rule.

This is the stage where patient input can influence design.

Start the Toolkit
How the Model Works

What Is the Proposed Rebate Model?

Hospitals purchase drugs at a discount. There is limited transparency into how those savings are used. Patients are not told when they receive a 340B drug.

Instead of upfront discounts, manufacturers would issue rebates tied to actual patient claims. This increases tracking and oversight.

When discounts are linked to claims data, it becomes clearer whether any savings benefit patients at the pharmacy counter or remain within hospital systems.

The Health Resources and Services Administration (HRSA) is asking for public input on how this model should be designed, put into practice, and monitored.

How to Write Your Comment


  1. Introduce Yourself
  2. Explain Your Experience
  3. Connect to the Rebate Model
  4. Close Clearly
Submit Your Comment Now

Key Themes to Consider

  • Transparency in billing
  • Disclosure of 340B Pricing
  • Out-of-pocket cost reduction
  • Medical debt concern
  • Program Accountability
  • Safeguards to Protect Access
  • Stronger Oversight and Reporting

Things to Avoid

  • Attacks on Hospitals
  • Technical policy jargon
  • Industry-specific language

    Keep it personal and respectful.

Sample Comment Letters

You may copy and paste this template into Regulations.gov.

Re: Docket No. HRSA-2026-03042
 Request for Information: 340B Rebate Model Pilot Program

Dear HRSA:

I am submitting this comment as a [patient / caregiver / concerned citizen].

[Briefly explain why healthcare affordability and transparency matter to you personally.]

The 340B program plays an important role in supporting healthcare providers and expanding services. At the same time, patients deserve transparency and accountability in how program savings are used.

[Add 1–2 sentences about why transparency is important to you — for example, confusion about bills, lack of disclosure, or desire for clearer reporting.]

As HRSA evaluates a potential rebate model, I encourage the agency to consider mechanisms that improve reporting, strengthen oversight, and ensure that savings are meaningfully connected to patient benefit.

Increased transparency can reinforce public trust and help confirm that the program is operating in alignment with its statutory purpose.

Thank you for the opportunity to provide comments.

Sincerely,
 [Name]

You may copy and paste this template into Regulations.gov.

Re: Docket No. HRSA-2026-03042
 Request for Information: 340B Rebate Model Pilot Program

To Whom It May Concern:

I am writing in response to the Health Resources and Services Administration’s Request for Information regarding the potential 340B rebate model.

I am a [patient / caregiver / family member / advocate] who is affected by prescription drug costs at the pharmacy counter [briefly explain your connection — condition, caregiver role, financial situation].

As a patient/caregiver, I believe the 340B program should clearly and measurably benefit patients. Today, many patients are not informed when a medication was purchased at a 340B discount, and there is limited transparency into how those savings are used.

[Add 2–3 sentences describing your experience with prescription costs, hospital billing, or lack of transparency.]

If HRSA considers implementing a rebate model, I urge the agency to prioritize transparency, accountability, and patient impact. Any new framework should ensure that savings are traceable and that patients understand whether those discounts reduce their out-of-pocket costs.

Patients deserve clarity and confidence that the program is working as intended.

Thank you for the opportunity to provide input.

Sincerely,
 [Name]
 [City, State]

You may copy and paste this template into Regulations.gov.

Re: Docket No. HRSA-2026-03042
 Request for Information: 340B Rebate Model Pilot Program

To Whom It May Concern:

I am writing regarding the potential 340B rebate model under consideration by HRSA.

I am a [patient / caregiver] who has experienced financial strain due to prescription drug costs.

[Describe briefly how high out-of-pocket costs have affected you — choosing between expenses, delaying refills, stress, medical debt, etc.]

When patients continue to face significant financial burdens, it is reasonable to ask whether available program discounts are reaching those they were intended to help.

If HRSA proceeds with a rebate-based structure, I encourage the agency to design it in a way that enhances transparency and strengthens accountability while protecting patient access.

For families like mine, greater clarity and meaningful cost relief would make a real difference.

Thank you for considering the patient perspective.

Respectfully,
 [Name]
 [City, State]

You may copy and paste this template into Regulations.gov.

Re: Docket No. HRSA-2026-03042
 Request for Information: 340B Rebate Model Pilot Program

To Whom It May Concern:

I am writing as a [patient living with ___ / caregiver to ___ / parent of a child with ___].

[Briefly describe your condition or situation and how often you rely on prescription medications.]

When I learned that hospitals participating in the 340B program are able to purchase medications at discounted prices, I was surprised to realize that patients like me are often not told when those discounts apply.

[Describe a specific moment: a high pharmacy bill, deductible shock, coinsurance burden, medical debt, etc.]

If HRSA moves forward with a rebate model, I hope the agency ensures that patients benefit directly from program savings and that transparency improves. Clear reporting standards and safeguards could help strengthen trust in the program and ensure it fulfills its original purpose.

For patients like me, even small cost reductions can make a meaningful difference.

Thank you for considering the perspective of patients who live with the financial realities of healthcare every day.

Respectfully,
 [Name]
 [City, State]

You may copy and paste this template into Regulations.gov.

Re: Docket No. HRSA-2026-03042
 Request for Information: 340B Rebate Model Pilot Program

I am a [patient/caregiver] who has experienced [brief description of cost burden or lack of transparency].

I urge HRSA to prioritize transparency and patient benefit when evaluating a 340B rebate model. Patients should know when discounts apply and whether those savings reduce out-of-pocket costs.

Thank you for the opportunity to comment.

Respectfully,
 [Name]
 [City, State]